Provider review
Believe Health Review: Four Peptides and Nothing to Check Them Against
Believe Health's peptide menu is four products, priced in the open before any questionnaire: NAD+ at $199 a month, sermorelin and PT-141 at $249, tesamorelin at $299. That part is easy to read. Everything a buyer would use to check the product is missing: no certificate of analysis, no named pharmacy, no named prescriber, and an address that is a mailbox number in Casper, Wyoming. The cards themselves describe mechanisms fairly and stretch in two places.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit Believe HealthOf Believe Health’s 4 dated product claims documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Four peptides at prices you can read before signing up, from a company that publishes no lab result, names no pharmacy and gives only a Wyoming mailbox as its address.
Worth trusting if
- You want the peptide price visible before any questionnaire, account or email
- You want tesamorelin or PT-141, the two molecules here with completed phase 3 trials
- You want a short menu of four products rather than a long list of blends
Be skeptical if
- You want to read a certificate of analysis, because this site publishes none
- You want to know who compounds your prescription, which it never says
- You want one clear cancellation rule, since the site states three
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Believe Health
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- NAD+ — $199/mo, the cheapest of the four peptides, quoted as a "from" floor.
- Sermorelin — $249/mo, quoted as a "from" floor.
- Tesamorelin — $299/mo, the dearest of the four, quoted as a "from" floor.
- PT-141 — $249/mo, quoted as a "from" floor.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 4 products reviewed here. The evidence concerns the molecule, not Believe Health's service.
4
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Believe Health’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
About the tesamorelin
NAD+NAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“Not a peptide but a coenzyme your cells run on — NAD+ replenishes the electron-carrying fuel that quietly thins as the decades add up.”
Read on the Believe Health site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
Calling NAD+ a coenzyme rather than a peptide is simply correct, and it is more than many sellers admit. The claim that matters is "replenishes": that an injection restores a pool that shrinks with age. No randomized trial of injected NAD+ has reported that, or any energy or aging outcome. The research usually cited is on oral precursors, which are different molecules by a different route.1
SermorelinSermorelin · Compounded (503A)Claim matches the trials
“A GHRH analog that asks your own pituitary to release growth hormone on its natural nightly schedule — rather than replacing the hormone from outside.”
Read on the Believe Health site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests recovery or sleep quality as an outcome in healthy adults. A parallel ClinicalTrials.gov search for sermorelin as an intervention returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
This card claims only what sermorelin is known to do. Its 19 randomized trials, the newest from 2005, measure growth hormone secretion, and a GHRH analog prompting the pituitary to release its own hormone is that finding in plain words. The outcomes buyers usually want are a separate matter: the product page's "recovery, body composition, and daytime energy" never appears as an outcome in that literature.2
TesamorelinTesamorelin · Compounded (503A)Claim reaches past the trials
“The stabilized GHRH analog studied specifically for the deep abdominal fat that resists diet and training.”
Read on the Believe Health site, September 2026
Phase 3 trials
What the trials show for Tesamorelin
- NCT00123253 — Phase 3, completed, n=412. The pivotal trial of tesamorelin in HIV patients with excess abdominal fat. The outcome measured was visceral abdominal fat, in that population.
- NCT00608023 — Phase 3, completed, n=263. The extension study in the same HIV-associated lipodystrophy population.
"Studied specifically for the deep abdominal fat" is accurate as far as it goes: two completed phase 3 trials measured visceral abdominal fat. Both enrolled adults with HIV-associated lipodystrophy. The card recasts that as fat "that resists diet and training", which describes a gym-goer rather than the patients who were studied, and the product page never names the population.3,4
PT-141Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“The peptide that starts in the brain rather than the bloodstream — PT-141 is studied for the melanocortin pathways tied to sexual desire, in women and men alike.”
Read on the Believe Health site, September 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder. One of the two trials behind the FDA approval of bremelanotide.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.
The brain-first description of bremelanotide is right, and "studied for" is a careful verb. "In women and men alike" is where it outruns the record: the two phase 3 trials, 1,437 participants, were all premenopausal women with hypoactive sexual desire disorder. The page also never tells a reader that an approved version of this molecule exists.5
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere. Each peptide page says "Believe Health protocols are prepared by partner compounding pharmacies in the United States", the footer carries a "COMPOUNDED IN USA" badge, and "503A" and "503B" appear nowhere on the site. No laboratory, prescriber or medical group is named either. Its terms ask the buyer to "voluntarily and unconditionally waive your right to have the prescription filled at a pharmacy of your choice", a waiver in favor of a party the site never identifies, and disclose that prescriptions "may not use child-resistant packaging".
Read on the Believe Health site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
Nothing is published. No page mentions a certificate of analysis, and no potency, purity or sterility result appears anywhere on the site, for the peptides or the GLP-1s. The "COMPOUNDED IN USA" badge is a statement about geography rather than about testing. To its credit, Believe Health makes no testing claim it cannot show.
Read on the Believe Health site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Believe Health describes its footprint several ways and publishes no list. The homepage banner reads "50-STATE CARE"; its FAQ says it "provides care via telehealth across the United States" while "availability of specific treatments depends on your location"; its contact page says it "operates via telehealth in the states where it is licensed". No exclusion is named.
Read the full licensing claim
"Reviewed by a licensed provider" and "Compounded in a U.S. pharmacy" at the top of the peptides page, plus a site-wide disclaimer referring to "state-licensed compounding pharmacies". No license number, prescriber or medical group is published.
Read on the Believe Health site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- All four peptide prices are on a public page before any questionnaire, from $199 to $299 a month.
- The sermorelin card claims a mechanism, the pituitary releasing its own growth hormone, which is exactly what the trials measured.
- The NAD+ card says plainly that NAD+ is "not a peptide but a coenzyme".
Show 4 more
- Tesamorelin and PT-141 are real molecules with completed phase 3 trials behind them.
- Its disclaimer states plainly that compounded medications are not FDA-approved and that their safety, efficacy and quality have not been independently verified by the FDA.
- It makes no testing claim it cannot support, and every product page says a licensed provider reviews each order.
- No FDA warning letter for the company.
- No certificate of analysis exists anywhere on the site, for any of the four peptides.
- No pharmacy, laboratory, prescriber or medical group is named, and the compounding class is never stated.
- The tesamorelin card sells "the deep abdominal fat that resists diet and training" from trials run in adults with HIV-associated lipodystrophy.
Show 7 more
- The PT-141 card says "in women and men alike", while both phase 3 trials enrolled only women.
- Its GLP-1 treatment pages promise "The price we quote is the price you pay, period" and print no price; the "from" figures, $129 for semaglutide and $149 for tirzepatide, appear only on the peptides page.
- Its terms ask you to waive the right to fill your prescription at a pharmacy of your choice, in favor of a company the site does not name.
- Three cancellation rules are live at once: 48 hours before the processing date in the terms, 30 days' notice in the treatment-page FAQ, and "cancel your subscription at any time" in the refund policy.
- Its terms say prescriptions may ship without child-resistant packaging, and impose a $35 disposal fee on returned medication under a policy that says it does not accept returns.
- The only address published is a mailbox number in Casper, Wyoming, on a site whose contact page says "Telehealth only".
- The peptide product pages still show "Other therapies to consider" cards for BPC-157 and MOTS-C that lead to a page that does not exist.
Verdict
The bottom line
Believe Health gets the easy part right: four peptides, four prices, visible before you hand over anything. The cards are fairer than most, with sermorelin described by what its trials measured and NAD+ called what it is. What you cannot do here is check anything: no lab report, no pharmacy, no prescriber, and a waiver of your choice of pharmacy in the terms. If you buy tesamorelin or PT-141, know that their evidence came from people unlike most buyers.
Opens Believe Health's website. A link is not a recommendation to take anything.
What it sells
Believe Health's peptide menu is four products, each a monthly "from" floor printed on the peptides page before any questionnaire:
| Peptide | Price | The card, in part |
|---|---|---|
| NAD+ | $199/mo | "Not a peptide but a coenzyme your cells run on…" |
| Sermorelin | $249/mo | "…asks your own pituitary to release growth hormone on its natural nightly schedule…" |
| PT-141 | $249/mo | "…studied for the melanocortin pathways tied to sexual desire, in women and men alike." |
| Tesamorelin | $299/mo | "…studied specifically for the deep abdominal fat that resists diet and training." |
The product pages still close with an "Other therapies to consider" row offering BPC-157 and MOTS-C. Both links lead to a page that does not exist.
Full analysis — 3 more sectionsWhat you can check, and what you cannot · The GLP-1 prices sit on the wrong page · What the trials show
What you can check, and what you cannot
No certificate of analysis appears anywhere on the site. No pharmacy is named: the peptide pages say only that protocols "are prepared by partner compounding pharmacies in the United States", and a footer badge reads "COMPOUNDED IN USA", which is a statement about geography. No laboratory, prescriber or medical group is named, and "503A" and "503B" never appear.
The address in the terms is 5830 E 2nd St, Ste 7000 #37006, Casper, Wyoming, a mailbox number, and the contact page says "By appointment · Telehealth only".
The terms add three things worth reading before you buy. Buying the service waives your right to have the prescription filled at a pharmacy of your choice. Prescriptions may ship without child-resistant packaging. And returned medication carries a $35 disposal fee, under a refund policy that says "we do not accept returns or exchanges".
Cancellation is stated three ways: up to 48 hours before the monthly processing date in the terms, "30 days' notice prior to the next billing cycle" in the treatment-page FAQ, and "You may cancel your subscription at any time" in the refund policy.
The GLP-1 prices sit on the wrong page
Believe Health also sells compounded GLP-1s. Its treatment pages promise "flat-rate pricing with zero hidden fees" and "The price we quote is the price you pay, period", then print no price. The figures appear on the peptides page instead: semaglutide from $129 a month, tirzepatide, microdose and oral from $149.
What the trials show
Sermorelin's card makes the one claim its trials support: a GHRH analog prompting the pituitary to release growth hormone. All 19 randomized trials, the newest from 2005, measured exactly that. 2 The product page's "recovery, body composition, and daytime energy" were never outcomes.
Tesamorelin has two completed phase 3 trials, 675 participants, measuring visceral fat in adults with HIV-associated lipodystrophy. 3 The card sells it for fat "that resists diet and training".
PT-141 rests on 1,437 premenopausal women with hypoactive sexual desire disorder, the basis of an FDA approval. 5 The card says "in women and men alike".
NAD+ is honestly called a coenzyme. Whether an injection "replenishes" it has no reported randomized trial; the research usually cited is on oral precursors. 1
Questions
Frequently asked questions
Which peptides does Believe Health sell?
Four: NAD+ from $199 a month, sermorelin and PT-141 from $249, and tesamorelin from $299. It also sells compounded GLP-1s.
Does Believe Health publish test results?
No. No page mentions a certificate of analysis, and no potency, purity or sterility result appears anywhere on the site. Its "COMPOUNDED IN USA" badge describes where, not what was tested.
What do its GLP-1s cost?
The treatment pages do not say, despite promising that "the price we quote is the price you pay". The peptides page lists semaglutide from $129 a month and tirzepatide from $149, as "from" floors.
Which pharmacy fills the prescription?
It never says, and its terms ask you to waive the right to choose one. The site refers only to "partner compounding pharmacies" and "state-licensed compounding pharmacies", names none of them, and never uses the words 503A or 503B.
How do I cancel?
The site gives three answers. The terms say up to 48 hours before the monthly processing date, the treatment-page FAQ asks for 30 days' notice before the next billing cycle, and the refund policy says you may cancel at any time. Medication already dispensed is not refunded under any of them.
Glossary
Key terms
Show definitions
- Certificate of analysis
- A laboratory report for one manufactured lot, giving identity, potency and sterility results against a specification. Believe Health publishes none.
- Pharmacy-choice waiver
- A term in which a buyer gives up the right to have a prescription dispensed at a pharmacy they select. Believe Health's terms contain one, without naming the pharmacy it operates in favor of.
Compare
Others selling what Believe Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
- Pallas HealthAlso sells NAD+ (nicotinamide adenine dinucleotide) · 4 of 4 claims match the trials
- ShedAlso sells Sermorelin · 4 of 6 claims match the trials
- CareBareRXAlso sells NAD+ (nicotinamide adenine dinucleotide) · 2 of 4 claims match the trials
- EdenAlso sells Sermorelin · 3 of 6 claims match the trials
Ranked
The lists Believe Health is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Believe Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 5 sources
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; and ClinicalTrials.gov search: intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England Journal of Medicine 357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Theratechnologies (2026). TH9507 in Patients With HIV-Associated Lipodystrophy, NCT00123253 — phase 3, completed, enrolment 412; and TH9507 Extension Study, NCT00608023 — phase 3, completed, enrolment 263. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00123253
- Kingsberg SA, Clayton AH, Portman D, Williams LA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology 134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.